Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 7;7(23):35423-36.
doi: 10.18632/oncotarget.8770.

Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma

Wei Wang  1   2 , Xiao-Long Chen  1   2 , Shen-Yu Zhao  3 , Yu-Hui Xu  3 , Wei-Han Zhang  1   2 , Kai Liu  1   2 , Xin-Zu Chen  1   2 , Kun Yang  1   2 , Bo Zhang  1 , Zhi-Xin Chen  1 , Jia-Ping Chen  1 , Zong-Guang Zhou  1   4 , Jian-Kun Hu  1   2
Affiliations

Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma

Wei Wang et al. Oncotarget. .

Abstract

The prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma (GC) has been widely reported and is still under debate. Here, we evaluated the prognostic significance of preoperative serum CA125, CA19-9 and CEA in patients with GC. 1692 patients with GC who underwent gastrectomy were divided into the training (from January 2005 to December 2011, n = 1024) and the validation (from January 2012 to December 2013, n = 668) cohorts. Positive groups of CA125 (> 13.72 U/ml), CA19-9 (> 23.36 U/ml) and CEA (> 4.28 ng/ml) were significantly associated with more advanced clinicopathological traits and worse outcomes than that of negative groups (all P < 0.01). In Cox regression analysis, tumor size (P < 0.001, P = 0.005), pTNM stage (P < 0.001, P < 0.001) and CA125 (P = 0.026, P = 0.005) were independent prognostic factors both in two cohorts. Nomograms of these two cohorts based on the number of positive serum tumor markers (NPTM) were more accurate in prognostic prediction than TNM stage alone. Our findings suggested that elevated preoperative serum CA125, CA19-9 and CEA were associated with more advanced clinicopathological traits and less favorable outcomes. In addition, CA125 as an independent prognostic factor should be further investigated. Nomogram based on NPTM could accurately predict the prognosis of GC patients.

Keywords: CA125; CA19-9; CEA; gastric cancer; tumor marker.

PubMed Disclaimer

Conflict of interest statement

The authors indicate no potential conflicts of interest.

Figures

Figure 1
Figure 1. Survival analysis of subgroups of CA125 (A), CA19-9 (B), CEA (C) and their combined detection (D) in the training cohort
There were significant differences on survival outcomes between positive and negative subgroups in CA125, CA19-9, CEA and their combined detection, respectively (all P < 0.001)
Figure 2
Figure 2. Nomogram of NPTM and clinicopathological traits in the training cohort
Figure 3
Figure 3. Calibration curve of nomogram in the training cohort
Figure 4
Figure 4. Survival analysis of subgroups of CA125 (A), CA19-9 (B), CEA (C) and their combined detection (D) in the validation cohort
There were significant differences on survival outcomes between positive and negative subgroups in CA125, CA19-9, CEA and their combined detection, respectively (all P < 0.001)
Figure 5
Figure 5. Nomogram of NPTM and clinicopathological traits in the validation cohort
Figure 6
Figure 6. Calibration curve of nomogram in the validation cohort
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sun XD, Mu R, Zhou YS, Dai XD, Zhang SW, Huangfu XM, Sun J, Li LD, Lu FZ, Qiao YL. Analysis of mortality rate of stomach cancer and its trend in twenty years in China [Article in Chinese] Zhonghua Zhong Liu Za Zhi. 2004;26:4–9. - PubMed
    1. Whiting J, Sano T, Saka M, Fukagawa T, Katai H, Sasako M. Follow-up of GC: a review. Gastric Cancer. 2006;9:74–81. - PubMed
    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. - PubMed
    1. Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM. Validation of new cancer biomarkers: a position statement from the European group on tumor markers. Clin Chem. 2015;61:809–820. - PubMed
    1. Beketic-Oreskovic L, Maric P, Ozretic P, Oreskovic D, Ajdukovic M, Levanat S. Assessing the clinical significance of tumor markers in common neoplasms. Front Biosci (Elite Ed) 2012;4:2558–2578. - PubMed